Inflammatory biomarkers predict outcomes of patients with radioactive iodine refractory thyroid cancer treated with sorafenib.

Meihua Jin Mijin KimMin Ji JeonEui Young KimDong Yeob ShinBo Hyun KimWon Bae KimYoung Kee ShongDong-Jun Lim Won Gu Kim

Published in: Endocrine (2023)

Baseline inflammatory biomarkers successfully predicted PFS and OS in patients with progressive RAI-refractory thyroid cancer treated with sorafenib. These prognostic biomarkers might help arrive at appropriate clinical decisions regarding the use of sorafenib.

Keyphrases

oxidative stress
multiple sclerosis
type diabetes
newly diagnosed
skeletal muscle
insulin resistance
glycemic control